The role of fecal calprotectin in assessment of hepatic encephalopathy in patients with liver cirrhosis

Acta Gastro-Enterologica Belgica

Volumn 77, Issue 3, 2014, Pages 302-305

  Alempijević, Tamara ^a,b   Štulić, Miloš ^a   Popovic, Dragan ^a,b   Culafic, Djordje ^a,b   Dragasevic, Sanja ^a   Milosavljevic, Tomica ^a,b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Fecal calprotectin; Hepatic encephalopathy; Liver cirrhosis; West Haven criteria

Indexed keywords

AMMONIA; CALGRANULIN; BIOLOGICAL MARKER;

ADULT; AMMONIA BLOOD LEVEL; ARTICLE; CHILD PUGH SCORE; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ASSOCIATION; DISEASE SEVERITY ASSESSMENT; EXPLORATORY RESEARCH; FECES LEVEL; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; NORMAL VALUE; NUMBER CONNECTION TEST; STAGING; WEST HAVEN CRITERIA; AGED; CASE CONTROL STUDY; FECES; METABOLISM; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FECES; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84922321683     PISSN: 17843227     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Fagerhol M.K., Dale I., Andersson T. Release and quantification of a leucocyte derived protein (L1). Scand. J. Haematol., 1980, 24: 393 - 8.
2. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful,magic, or unnecessary toys? Gut, 2006, 55: 426-31.
3. D'Inca R., Dal Pont E., Di Leo V. et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am. J. Gastroenterol., 2008, 103: 2007- 14.
4. Gundling F., Schmidtler F., Hapfelmeier A. et al. Fecal Calprotectin is a Useful Screening Parameter for Hepatic Encephalopathy and Spontaneous Bacterial Peritonitis in Cirrhosis. Liver Int., 2011, 31 (9): 1406- 15.
5. Gunnarsdottir S.A., Sadik R., Shev S. et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am. J. Gastroenterol., 2003, 98: 1362-70.
6. Tibble J., Sigthorsson G., Foster R., Sherwood R., Fagerhol M., Bjarnason I. Fecal calprotectin and fecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut, 2001, 49 (3): 402-8.
7. Wildt S., Nordgaard-Lassen I., Bendtsen F., Rumessen J.J. Metabolic and inflammatory fecal markers in collagenous colitis. Eur. J. Gastroenterol. Hepatol., 2007, 19 (7): 567-74.
8. Shastri Y.M., Bergis D., Povse N. et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am. J. Med., 2008, 121 (12): 1099-106.
9. Maiden L., Thjodleifsson B., Theodors A., Gonzalez J., Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterol., 2005, 128 (5): 1172-8.
10. Summerton C.B., Longlands M.G., Wiener K., Shreeve D.R. Fecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur. J. Gastroenterol. Hepatol., 2002, 14 (8): 841-5.
11. Roseth A.G., Kristinsson J., Fagerhol M.K. et al. Fecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand. J. Gastroenterol., 1993, 28 (12): 1073-6.
12. Ferenci P., Lockwood A., Mullen K., Tarter R., Weissenborn K., Blei A.T.; and the Members of the Working Party. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatol., 2002, 35: 716-21.
13. Schomerus H., Hamster W. Neuropsychological aspects of portalsystemic encephalopathy. Metab. Brain Dis., 1998, 13: 361-77.
14. Conn HO. Trailmaking and number-connection tests in the assesment of mental state in portal systemic encephalopathy. Dig. Dis., 1977, 22: 541-50.
15. Fagerhol M.K. Calprotectin, a fecal marker of organic gastrointestinal abnormality. Lancet, 2000, 356: 1783-4.
16. Van Rheenen P.F., Van de Vijver E., Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ, 2010, 341: c3369, 11 pp.
17. Schoepfer A.M., Trummler M., Seeholzer P. et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm. Bowel Dis., 2008, 14: 32-9.
18. Garcia-Tsao G.,Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best. Pract. Res. Clin. Gastroenterol., 2004, 18: 353-72.
19. Yagmur E., Schnyder B., Scholten D. et al. Elevated concentrations of fecal calprotectin in patients with liver cirrhosis. Dtsch. Med. Wochenschr., 2006, 131: 1930-4.
20. Joshi S., Lewis S.J., Creanor S., Ayling R.M. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann. Clin. Biochem., 2010, 47: 259-63.
21. Kant P., Fazakerley R., Hull M.A. Fecal calprotectin levels before and after weight loss in obese and overweight subjects. Int. J. Obes., 2013, 37 (2): 317-9.